Maharashtra Herald

Anaplastic Thyroid Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Anaplastic Thyroid Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

September 30
14:34 2022
Anaplastic Thyroid Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Anaplastic Thyroid Cancer pipeline constitutes 8+ key companies continuously working towards developing 8+ Anaplastic Thyroid Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Anaplastic Thyroid Cancer Overview

Anaplastic thyroid carcinoma, also known as undifferentiated thyroid carcinoma, is a rare, highly aggressive malignant tumor accounting for 2 to 3 percent of all thyroid gland neoplasms. Anaplastic thyroid carcinoma continues to be one of the most deadly diseases worldwide and carries a very poor prognosis. The recommended treatment for anaplastic thyroid carcinoma is based on surgery when feasible and chemoradiation either concurrently or sequentially.

 

Anaplastic Thyroid Cancer Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anaplastic Thyroid Cancer Market. 

 

The Anaplastic Thyroid Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Anaplastic Thyroid Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Anaplastic Thyroid Cancer treatment therapies with a considerable amount of success over the years. Anaplastic Thyroid Cancer Key players such as – AffyImmune Therapeutics, Faron Pharmaceuticals Ltd, Codiak BioSciences, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD,  Merck & Co., Takeda Oncology, and others, are developing therapies for the Anaplastic Thyroid Cancer treatment 
  • Anaplastic Thyroid Cancer Emerging therapies such as – AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others are expected to have a significant impact on the Anaplastic Thyroid Cancer market in the coming years. 
  • In February 2022, Stanford University in collaboration with Merck Sharp & Dohme LLC initiated a Phase II trial of Pembrolizumab in metastatic or locally advanced anaplastic/undifferentiated thyroid cancer. This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab therapy in anaplastic thyroid cancer in patients with no curative alternative therapy. Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
  • In October 2016, Stanford University in collaboration with Merck Sharp & Dohme LLC initiated a Phase II trial of Pembrolizumab in metastatic or locally advanced anaplastic/ undifferentiated thyroid cancer. The goal of this multi-center, open-label trial was to measure the impact of treating metastatic anaplastic thyroid cancer patients with immune checkpoint therapy 

 

Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment

  • Anaplastic Thyroid Cancer Assessment by Product Type
  • Anaplastic Thyroid Cancer By Stage and Product Type
  • Anaplastic Thyroid Cancer Assessment by Route of Administration
  • Anaplastic Thyroid Cancer By Stage and Route of Administration
  • Anaplastic Thyroid Cancer Assessment by Molecule Type
  • Anaplastic Thyroid Cancer by Stage and Molecule Type 

 

DelveInsight’s Anaplastic Thyroid Cancer Report covers around 8+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Anaplastic Thyroid Cancer Drugs Under Different Phases of Clinical Development Include:

  • AIC100: AffyImmune Therapeutics
  • FP-1305: Faron Pharmaceuticals Ltd
  • CDK-002: Codiak BioSciences
  • HLX208: Shanghai Henlius Biotech
  • HX008: Taizhou Hanzhong biomedical co. LTD
  • Pembrolizumab: Merck & Co.
  • Sapanisertib: Takeda Oncology 

 

Get a Free Sample PDF Report to know more about Anaplastic Thyroid Cancer Pipeline Assessment

 

Anaplastic Thyroid Cancer Pipeline Analysis:

 

The Anaplastic Thyroid Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Anaplastic Thyroid Cancer treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
  • Anaplastic Thyroid Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Anaplastic Thyroid Cancer product details are provided in the report. Download the Anaplastic Thyroid Cancer pipeline report to learn more about the emerging Anaplastic Thyroid Cancer therapies

 

Anaplastic Thyroid Cancer Pipeline Market Drivers

  • Rising prevalence of thyroid cancer
  • Improving Healthcare Infrastructure
  • Demand for New and Effective Drugs
  • Increasing awareness about anaplastic thyroid cancer

 

Anaplastic Thyroid Cancer Pipeline Market Barriers

  • High cost of treatment
  • Adverse effects associated with the chemotherapy

 

Scope of Anaplastic Thyroid Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key Anaplastic Thyroid Cancer Companies: AffyImmune Therapeutics, Faron Pharmaceuticals Ltd, Codiak BioSciences, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD,  Merck & Co., Takeda Oncology, and others
  • Key Anaplastic Thyroid Cancer Therapies: AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others
  • Anaplastic Thyroid Cancer Therapeutic Assessment: Anaplastic Thyroid Cancer current marketed and Anaplastic Thyroid Cancer emerging therapies
  • Anaplastic Thyroid Cancer Market Dynamics:  Anaplastic Thyroid Cancer market drivers and Anaplastic Thyroid Cancer market barriers 

 

Request for Sample PDF Report for Anaplastic Thyroid Cancer Pipeline Assessment and clinical trials 

 

Table of Contents

1

Anaplastic Thyroid Cancer Report Introduction

2

Anaplastic Thyroid Cancer Executive Summary

3

Anaplastic Thyroid Cancer Overview

4

Anaplastic Thyroid Cancer- Analytical Perspective In-depth Commercial Assessment

5

Anaplastic Thyroid Cancer Pipeline Therapeutics

6

Anaplastic Thyroid Cancer Late Stage Products (Phase II/III)

7

Anaplastic Thyroid Cancer Mid Stage Products (Phase II)

8

Anaplastic Thyroid Cancer Early Stage Products (Phase I)

9

Anaplastic Thyroid Cancer Preclinical Stage Products

10

Anaplastic Thyroid Cancer Therapeutics Assessment

11

Anaplastic Thyroid Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Anaplastic Thyroid Cancer Key Companies

14

Anaplastic Thyroid Cancer Key Products

15

Anaplastic Thyroid Cancer Unmet Needs

16 

Anaplastic Thyroid Cancer Market Drivers and Barriers

17

Anaplastic Thyroid Cancer Future Perspectives and Conclusion

18

Anaplastic Thyroid Cancer Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Anaplastic Thyroid Cancer drugs and therapies  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories